期刊的影响因子--文章列表

期刊文章列表
Weirong Kang^1,2,3，Yuwei Liu^1,2,3，Weiping Wang^1,2,3（State Key Laboratory of Pharmaceutical Biotechnology，the University of Hong Kong；Department of Pharmacology and Pharmacy，Li Ka Shing Faculty of Medicine，the University of Hong Kong；Laboratory of Molecular Engineering and Nanomedicine，Dr.Li Dak-Sum Research Centre，the University of Hong Kong）.Light-responsive nanomedicine for cancer immunotherapy[J].Acta Pharmaceutica Sinica B,2023,第6期 Tao Liang^1,2，Fengli Wang³，Reham M.Elhassan²，Yongmei Cheng¹，Xiaolei Tang^3,4，Wengang Chen¹，Hao Fang²，Xuben Hou²（Department of Pharmacy，the Second Hospital Affiliated Wannan Medical College；Department of Medicinal Chemistry and Key Laboratory of Chemical Biology(Ministry of Education)，School of Pharmaceutical Sciences，Cheeloo College of Medicine，Shandong University；Department of Science and Education，Translational Medicine Center & Vascular Disease Research Center，the Second Hospital Affiliated Wannan Medical College；Clinical Pathogens Detection Engineering Center of Wuhu）.Targeting histone deacetylases for cancer therapy：Trends and challenges[J].Acta Pharmaceutica Sinica B,2023,第6期 Yaochen Xie¹，Qian Zhou²，Qiaojun He¹，Xiaoyi Wang，Jincheng Wang¹（Center for Drug Safety Evaluation and Research，Zhejiang Province Key Laboratory of Anti-Cancer Drug Research，College of Pharmaceutical Sciences，Zhejiang University；Department of Pharmacy，Hangzhou Medical College；Department of Nephrology，the First Affiliated Hospital of Huzhou Teachers College，the First People’s Hospital of Huzhou）.Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition[J].Acta Pharmaceutica Sinica B,2023,第6期 Bingwei Wang¹，Yan Ma¹，Sheng Li²，Hang Yao²，Mingna Gu¹，Ying Liu¹，You Xue¹，Jianhua Ding²，Chunmei Ma²，Shuo Yang²，Gang Hu^1,2（School of Medicine & Holistic Integrative Medicine，Nanjing University of Chinese Medicine；School of Basic Medical Sciences，Nanjing Medical University）.GSDMD in peripheral myeloid cells regulates microglial immune training and neuroinflammation in Parkinson’s disease[J].Acta Pharmaceutica Sinica B,2023,第6期 Wenxin Zhang¹，Xiaohui Pan¹，Yanjun Xu²，Hongjie Guo¹，Mingming Zheng¹，Xi Chen¹，Honghai Wu¹，Fengming Luan³，Qiaojun He^1,4,5，Ling Ding¹，Bo Yang^1,4（Zhejiang Province Key Laboratory of Anti-Cancer Drug Research，Institute of Pharmacology and Toxicology，College of Pharmaceutical Sciences，Zhejiang University；Department of Medical Thoracic Oncology，the Cancer Hospital of University of Chinese Academy of Sciences(Zhejiang Cancer Hospital)，Chinese Academy of Sciences；Department of Gastrointestinal Surgery，Second Affiliated Hospital of Zhejiang University，School of Medicine；The Innovation Institute for Artificial Intelligence in Medicine，Zhejiang University；Cancer Center of Zhejiang University）.Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA[J].Acta Pharmaceutica Sinica B,2023,第6期 Nan Ru¹，Wan-Yang Sun¹，Hua-Jun Wang¹，Yan-Ping Wu¹，Xiao-Fei Zheng¹，Rong-Rong He^1,2（The First Affiliated Hospital/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education(MOE)/Guangdong Engineering Research Center of Chinese Medicine & Disease Susceptibility/Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research，Jinan University；State Key Laboratory of Quality Research in Chinese Medicine，Macau University of Science and Technology）.Commentary：A nearly forgotten class of anti-inflammatory lipid molecules in central nervous system[J].Acta Pharmaceutica Sinica B,2023,第6期 Yue Chen¹，Jianing Song²，Yihang Cui²，Liyun Zhou²（Dongzhimen Hospital，Beijing University of Chinese Medicine；Pharmcube (Beijing) Co.，Ltd.）.Five trends of China’s pharmaceutical industry in 2022[J].Acta Pharmaceutica Sinica B,2023,第6期 Wei He^1,2，Alejandro Sosnik³，Chenjie Xu⁴（School of Pharmacy，China Pharmaceutical University；Shanghai Skin Disease Hospital，Tongji University School of Medicine；Laboratory of Pharmaceutical Nanomaterials Science，Department of Materials Science and Engineering，Technion-Israel Institute of Technology；Department of Biomedical Engineering，City University of Hong Kong）.Editorial of Special Column on Delivery Nanotechnologies to Modulate the Immune System and Combat Inflammation and Infection[J].Acta Pharmaceutica Sinica B,2023,第6期 Wei He，Alejandro Sosnik，Chenjie Xu（School of Pharmacy；Shanghai Skin Disease Hospital；Laboratory of Pharmaceutical Nanomaterials Science；Department of Biomedical Engineering）.Editor Profile：Guest Editor of Special Column on Delivery Nanotechnologies to Modulate the Immune System and Combat Inflammation and Infection[J].Acta Pharmaceutica Sinica B,2023,第6期 Jiang Wu，Wenfeng Gou，Zhiyun Wang，Huajie Chang，Deguan Li，Wenbin Hou，Changxiao Liu（Department of Pharmaceutical Engineering；Institute of Radiation Medicine；School of Chinese Materia Medica；Research Center for New Drug Evaluation）.Author correction to ‘Discovery of the radioprotecting effect of ecliptae herba，its constituents and targeting p53-mediated apoptosis in vitro and in vivo' [Acta Pharm Sin B 13 (2023) 1216-1230)[J].药学学报(英文版),2023,第6期 Yun Teng，Yixue Huang，Hao Yu，Cenhao Wu，Qi Yan，Yingjie Wang，Ming Yang，Haifeng Xie，Tianyi Wu，Huilin Yang，Jun Zou（Department of Orthopaedic Surgery，the First Affiliated Hospital of Soochow University）.Nimbolide targeting SIRT1 mitigates intervertebral disc degeneration by reprogramming cholesterol metabolism and inhibiting inflammatory signaling[J].Acta Pharmaceutica Sinica B,2023,第5期 Ruifang Han，Yu Xiao，Qianqian Bai，Chung Hang Jonathan Choi（Department of Biomedical Engineering，the Chinese University of Hong Kong）.Self-therapeutic metal-based nanoparticles for treating inflammatory diseases[J].Acta Pharmaceutica Sinica B,2023,第5期 Wei Wei，Qingxuan Zeng，Yan Wang，Xixi Guo，Tianyun Fan，Yinghong Li，Hongbin Deng，Liping Zhao，Xintong Zhang，Yonghua Liu，Yulong Shi，Jingyang Zhu，Xican Ma，Yanxiang Wang，Jiandong Jiang，Danqing Song（Institute of Medicinal Biotechnology，Chinese Academy of Medical Sciences and Peking Union Medical College）.Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects[J].Acta Pharmaceutica Sinica B,2023,第5期 Chuan Hu，Yujun Song，Yiwei Zhang，Siqin He，Xueying Liu，Xiaotong Yang，Tao Gong，Yuan Huang，Huile Gao（Key Laboratory of Drug Targeting and Drug Delivery Systems，West China School of Pharmacy，Sichuan University）.Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome[J].Acta Pharmaceutica Sinica B,2023,第5期 Jie Chen，Xiaohong Wei，Qian Zhang，Yuzhuo Wu，Guiyang Xia，Huan Xia，Lingyan Wang，Hongcai Shang，Sheng Lin（Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing，Dongzhimen Hospital，Beijing University of Chinese Medicine）.The traditional Chinese medicines treat chronic heart failure and their main bioactive constituents and mechanisms[J].Acta Pharmaceutica Sinica B,2023,第5期 Chuanfeng Tang¹，Qiaona Wang¹，Jingyan Shen¹，Congying Wang¹，Hong Ding¹，Shiyu Wen¹，Fan Yang¹，Ruiqing Jiao¹，Xingxin Wu¹，Jianmei Li¹，Lingdong Kong^1,2（State Key Laboratory of Pharmaceutical Biotechnology，School of Life Sciences，Nanjing University；State Key Laboratory of Natural Medicines，China Pharmaceutical University）.Neuron stem cell NLRP6 sustains hippocampal neurogenesis to resist stress-induced depression[J].Acta Pharmaceutica Sinica B,2023,第5期 Fuhua Wu，Shuang Luo，Yongshun Zhang，Yangsen Ou，Hairui Wang，Zhaofei Guo，Chunting He，Shuting Bai，Penghui He，Min Jiang，Xiaoyan Chen，Guangsheng Du，Xun Sun（Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province，Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology，West China School of Pharmacy，Sichuan University）.Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity[J].Acta Pharmaceutica Sinica B,2023,第5期 Jiang Xu^1,2，Shuai Guo^1,2，Xianmei Yin¹，Mingqian Li³，He Su⁴，Xuejiao Liao⁵，Qiushi Li²，Liang Le²，Shiyu Chen^1,2，Baosheng Liao⁴，Haoyu Hu²，Juan Lei²，Yingjie Zhu⁶，Xiaohui Qiu⁴，Lu Luo²，Jun Chen，Ruiyang Cheng²，Zhenzhan Chang⁸，Han Zhang⁹，Nicholas Chieh Wu¹⁰，Yiming Guo¹¹，Dianyun Hou¹²，Jin Pei¹，Jihai Gao¹，Yan Hua¹³，Zhihai Huang⁴，Shilin Chen^1,2（Institute of Herbgenomics，State Key Laboratory of Southwest Chinese Medicine Resources，Pharmacy College，Chengdu University of Traditional Chinese Medicine；Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences；Key Laboratory of Cancer Prevention and Therapy Combining Traditional Chinese and Western Medicine of Zhejiang Province，Zhejiang Academy of Traditional Chinese Medicine，Tongde Hospital of Zhejiang Province；Guangdong Provincial Hospital of Chinese Medicine(the Second Clinical Medical College of Guangzhou University of Chinese Medicine，Guangdong Provincial Hospital of Traditional Chinese Medicine)；Pharmacy College，Shandong University of Traditional Chinese Medicine；Department of Pathology，Memorial Sloan Kettering Cancer Center；Beijing Engineering Research Center of Pediatric Surgery，Engineering and Transformation Center，Beijing Children’s Hospital，National Center for Children’s Health，Capital Medical University；School of Basic Medical Sciences，Peking University；School of Chinese Materia Medica，Tianjin University of Traditional Chinese Medicine；School of Life and Environmental Sciences，the University of Sydney；University of Pittsburgh，Kenneth P.Dietrich School of Arts and Sciences；Agricultural College，Henan University of Science and Technology；Guangdong Provincial Key Laboratory of Silviculture，Protection and Utilization，Guangdong Academy of Forestry）.Genomic, transcriptomic, and epigenomic analysis of a medicinal snake, Bungarus multicinctus, to provides insights into the origin of Elapidae neurotoxins[J].Acta Pharmaceutica Sinica B,2023,第5期 Binghe Xu¹，Qingyuan Zhang²，Xichun Hu³，Qing Li¹，Tao Sun⁴，Wei Li⁵，Quchang Ouyang⁶，Jingfen Wang⁷，Zhongsheng Tong⁸，Min Yan⁹，Huiping Li¹⁰，Xiaohua Zeng¹¹，Changping Shan¹²，Xian Wang¹³，Xi Yan¹⁴，Jian Zhang³，Yue Zhang²，Jiani Wang¹，Liang Zhang⁴，Ying Lin¹⁵，Jifeng Feng¹⁶，Qianjun Chen¹⁷，Jian Huang¹⁸，Lu Zhang¹⁹，Lisong Yang¹⁹，Ying Tian¹⁹，Hongyan Shang¹⁹（Department of Medical Oncology and State Key Laboratory of Molecular Oncology，National Cancer Cener/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College；Department of Medical Oncology，Harbin Medical University Cancer Hospital；Department of Medical Oncology，Fudan University Shanghai Cancer Center；Department of Galactophore，Liaoning Cancer Hospital & Institute；Department of Oncology，the First Hospital of Jilin University；Department of Galactophore，Hunan Cancer Hospital；Department of Galactophore，Linyi Cancer Hospital；Department of Breast Medical Oncology，Tianjin Medical University Cancer Institute & Hospital；Department of Breast Disease，Henan Breast Cancer Center，the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital；Department of Breast Oncology，Beijing Cancer Hospital；Breast Cancer Center，Chongqing University Cancer Hospital；Department of Breast and Thyroid Oncology，Affiliated Hospital of Jining Medical University；Department of Medical Oncology，Run Run Shaw Hospital，Affiliated Hospital of Zhejiang University；Department of Head and Heck Oncology，West China Hospital，Sichuan University；Department of Thyroid & Breast Surgery，the First Affiliated Hospital of Sun Yat-sen University；Department of Medical Oncology，Jiangsu Cancer Hospital；Department of Galactophore，Guangdong Hospital of Traditional Chinese Medicine；Department of Oncological Surgery，the Second Affiliated Hospital，Zhejiang University School of Medicine；Taizhou EOC Pharma Co.Ltd.）.Entinostat, a class Ⅰ selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer：A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial[J].Acta Pharmaceutica Sinica B,2023,第5期 Mingyan Li¹，Yaling Wang^1,2，Lingzhi Zhang¹，Changxing Gao¹，Jing J.Li¹，Jiandong Jiang¹，Qing Zhu¹（State Key Laboratory of Bioactive Substance and Function of Natural Medicines，and Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study，Chinese Academy of Medical Sciences and Peking Union Medical College；College of Chinese Materia Medica and Yunnan Key Laboratory of Southern Medicinal Utilization，Yunnan University of Chinese Medicine）.Berberine improves central memory formation of CD8⁺ T cells：Implications for design of natural product-based vaccines[J].Acta Pharmaceutica Sinica B,2023,第5期 Rolande Meudom^1,2，Yanxian Zhang¹，Michael A.Vanden Berg³，Lei Zou³，Yi Wolf Zhang^1,2，Matthew J.Webber³，Danny Hung-Chieh Chou¹（Division of Endocrinology and Diabetes，Department of Pediatrics，School of Medicine，Stanford University；Department of Biochemistry，School of Medicine，University of Utah；Department of Chemical Engineering，University of Notre Dame）.Supramolecular approaches for insulin stabilization without prolonged duration of action[J].Acta Pharmaceutica Sinica B,2023,第5期 Bin Tu^1,2，Yanrong Gao^1,2，Xinran An^1,3，Huiyuan Wang¹，Yongzhuo Huang^1,2,4,5,6（State Key Laboratory of Drug Research，Shanghai Institute of Materia Medica，Chinese Academy of Sciences；University of Chinese Academy of Sciences；University of Michigan College of Pharmacy；Zhongshan Institute for Drug Discovery，SIMM，CAS；NMPA Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients；Taizhou University，School of Advanced Study，Institute of Natural Medicine and Health Product）.Localized delivery of nanomedicine and antibodies for combating COVID-19[J].Acta Pharmaceutica Sinica B,2023,第5期 Rania Awad¹，Avi Avital²，Alejandro Sosnik¹（Laboratory of Pharmaceutical Nanomaterials Science，Department of Materials Science and Engineering，Technion-Israel Institute of Technology；Behavioral Neurobiology Laboratory，Department of Occupational Therapy，Faculty of Social Welfare and Health Sciences，University of Haifa）.Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders[J].Acta Pharmaceutica Sinica B,2023,第5期 Damijan Knez¹，Daniel Diez-Iriepa^2,3，Mourad Chioua^2,3，Andrea Gottinger⁴，Milica Denic⁵，Fabien Chantegreil⁵，Florian Nachon⁵，Xavier Brazzolotto⁵，Anna Skrzypczak-Wiercioch⁶，An?e Meden¹，Anja Pi?lar¹，Janko Kos¹，Simon ?akelj¹，Jure Stojan⁷，Kinga Sa?at⁸，Julia Serrano⁹，Ana Patricia Fernández⁹，Aitana Sánchez-García¹⁰，Ricardo Martínez-Murillo⁹，Claudia Binda⁴，Francisco López-Mu?oz¹¹，Stanislav Gobec¹，José Marco-Contelles²（University of Ljubljana，Faculty of Pharmacy；Laboratory of Medicinal Chemistry(Institute of Organic Chemistry，CSIC)；Departamento de Química Orgánicay Química Inorgánica；Department of Biology and Biotechnology，University of Pavia；Département de Toxicologie et Risques Chimiques，Institut de Recherche Biomédicale des Armées；Department of Animal Anatomy and Preclinical Sciences，University Centre of Veterinary Medicine JU-UA，University of Agriculture in Krakow；Institute of Biochemistry，Faculty of Medicine，University of Ljubljana；Department of Pharmacodynamics，Chair of Pharmacodynamics，Faculty of Pharmacy，Jagiellonian University Medical College；Department of Translational Neurobiology，Neurovascular Research Group，Cajal Institute(CSIC)；Biotechnology and Vegetal Biology Department，Escuela Técnica Superior de Ingeniería Agronómica，Alimentaria y de Biosistemas，Universidad Politécnica de Madrid；Faculty of Health，Camilo José Cela University of Madrid(UCJC)，Neuropsychopharmacology Unit，"Hospital 12 de Octubre" Research Institute）.8-Hydroxyquinolylnitrones as multifunctional ligands for the therapy of neurodegenerative diseases[J].Acta Pharmaceutica Sinica B,2023,第5期 Shuye Lin¹，Hanli Xu²，Lin Qin³，Mengdi Pang²，Ziyu Wang¹，Meng Gu¹，Lishu Zhang¹，Cong Zhao¹，Xuefeng Hao¹，Zhiyun Zhang¹，Weimin Ding³，Jianke Ren⁴，Jiaqiang Huang^1,2（Cancer Research Center，Beijing Chest Hospital，Capital Medical University，Beijing Tuberculosis and Thoracic Tumor Institute；College of Life Sciences & Bioengineering，Beijing Jiaotong University；Department of Endoscopic Diagnosis and Treatment，Beijing Chest Hospital，Capital Medical University，Beijing Tuberculosis and Thoracic Tumor Institute；CAS Key Laboratory of Computational Biology，Shanghai Institute of Nutrition and Health，University of Chinese Academy of Sciences，Chinese Academy of Sciences）.UHRF1/DNMT1—MZF1 axis-modulated intragenic site-specific CpGI methylation confers divergent expression and opposing functions of PRSS3 isoforms in lung cancer[J].Acta Pharmaceutica Sinica B,2023,第5期 Duo Xu^1,2,3，Fan Yang^2,3，Jiayao Chen^1,3，Tianxing Zhu^2,3，Fen Wang⁴，Yitai Xiao^2,3，Zibin Liang³，Lei Bi³，Guolong Huang³，Zebo Jiang^2,3，Hong Shan^1,3，Dan Li^2,3（Center for Interventional Medicine，the Fifth Affiliated Hospital，Sun Yat-sen University；Department of Nuclear Medicine，the Fifth Affiliated Hospital，Sun Yat-sen University；Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging，the Fifth Affiliated Hospital，Sun Yat-sen University；Department of Pathology，the First Affiliated Hospital，Sun Yat-sen University）.Novel STING-targeted PET radiotracer for alert and therapeutic evaluation of acute lung injury[J].Acta Pharmaceutica Sinica B,2023,第5期 Lijuan Ma¹，Jing Zhang¹，Ling Lin¹，Tuanjie Wang²，Chaofu Ma¹，Xiaomeng Wang¹，Mingshuang Li¹，Yanjiang Qiao¹，Yongxiang Wang³，Guimin Zhang⁴，Zhisheng Wu¹（Beijing University of Chinese Medicine，Engineering Research Center for Pharmaceutics of Chinese Materia Medica and New Drug Development，Ministry of Education；Jiangsu Kanion Pharmaceutical Co.Ltd.，State Key Laboratory of New Technology in Pharmaceutical Process of Traditional Chinese Medicine；Yangtze River Pharmaceutical (Group) Co.Ltd.，State Pharmaceutical Engineering Technology Research Center of Traditional Chinese Medicine；Lunan Pharmaceutical Group Co.Ltd.，State Key Laboratory of Generic Technology of Traditional Chinese Medicine）.Data-driven engineering framework with AI algorithm of Ginkgo Folium tablets manufacturing[J].Acta Pharmaceutica Sinica B,2023,第5期 Huitong Ruan^1,2，Yongfang Li³，Cheng Wang⁴，Yixu Jiang⁴，Yulong Han^5,6，Yiwei Li^5,6，Dandan Zheng¹，Jing Ye⁴，Gang Chen²，Guo-yuan Yang⁴，Lianfu Deng¹，Ming Guo⁵，Xingcai Zhang⁶，Yaohui Tang⁴，Wenguo Cui¹（Department of Orthopaedics，Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases，Shanghai Institute of Traumatology and Orthopaedics，Ruijin Hospital，Shanghai Jiao Tong University School of Medicine；Jiaxing Key Laboratory of Basic Research and Clinical Translation on Orthopedic Biomaterials，Department of Orthopaedics，the Second Affiliated Hospital of Jiaxing University；Department of Rehabilitation Medicine，Ruijin Hospital，School of Medicine，Shanghai Jiao Tong University；Med-X Research Institute and School of Biomedical Engineering，Shanghai Jiao Tong University；School of Engineering，Massachusetts Institute of Technology；School of Engineering and Applied Sciences，Harvard University）.Click chemistry extracellular vesicle/peptide/chemokine nanocarriers for treating central nervous system injuries[J].Acta Pharmaceutica Sinica B,2023,第5期 Endong Zhang¹，Philana Phan¹，Zongmin Zhao^1,2（Department of Pharmaceutical Sciences，College of Pharmacy，University of Illinois Chicago；Translational Oncology Program，University of Illinois Cancer Center）.Cellular nanovesicles for therapeutic immunomodulation：A perspective on engineering strategies and new advances[J].Acta Pharmaceutica Sinica B,2023,第5期首页上一页 5 6 7 8 9 下一页尾页共有12页，转到页

期刊文章列表